Why did the FDA refuse Moderna's flu vaccine?
FDA declines to accept Moderna’s mRNA influenza application
U.S. regulators refused to move forward with Moderna’s request to license an mRNA-based influenza vaccine after concluding that the company compared its candidate against a flu shot that was not the best standard of care. The Food and Drug Administration said the choice of comparator in Moderna’s pivotal trial undermined the application’s suitability for review. Moderna has asked for a meeting to discuss the refusal.
This decision matters because it interrupts a high-profile effort to bring mRNA technology — already used for COVID-19 vaccines — into routine seasonal influenza protection. The refusal does not necessarily mean the vaccine is unsafe or ineffective; rather, it reflects procedural and evidentiary concerns about how Moderna designed its trial and whether the results can reliably show an improvement over existing options.
Key implications
- For vaccine developers: The FDA’s stance signals close scrutiny of trial design and comparator choices for next-generation vaccines, potentially forcing companies to align trials with current standards of care.
- For public health: Delays in new vaccine types could slow deployment of potentially more adaptable influenza shots, especially in seasons when circulating strains shift.
- For patients and clinicians: Short-term impact is limited—current flu vaccines remain available—but the pipeline for novel platforms may face added regulatory hurdles.
What happens next
- Moderna can seek formal meetings with the FDA to address reviewers’ concerns.
- The company might rework its trial evidence or run additional studies using an accepted comparator.
- Broader industry-watchers will monitor whether the decision affects other applications for updated or novel respiratory vaccines.
At stake is not only a single product but also regulatory clarity on how to evaluate new vaccine technologies against established standards of care.